Natural Product (NP) Details
| General Information of the NP (ID: NP8924) | |||||
|---|---|---|---|---|---|
| Name |
Alpha linolenic acid
|
||||
| Synonyms |
linolenic acid; alpha-Linolenic acid; 463-40-1; linolenate; (9Z,12Z,15Z)-octadeca-9,12,15-trienoic acid; a-Linolenic acid; cis,cis,cis-9,12,15-Octadecatrienoic acid; all-cis-9,12,15-Octadecatrienoic acid; 9-cis,12-cis,15-cis-Octadecatrienoic acid; 9,12,15-Octadecatrienoic acid, (Z,Z,Z)-; (Z,Z,Z)-9,12,15-Octadecatrienoic acid; (9,12,15)-linolenic acid; Linolenic acid (8CI); alpha-Lnn; 9Z,12Z,15Z-Octadecatrienoic acid; Industrene 120; 9,12,15-Octadecatrienoic acid; CCRIS 656; (9Z,12Z,15Z)-Octadecatrienoic acid; UNII-0RBV727H71; .alpha.-Linolenic acid; CHEMBL8739; cis-delta9,12,15-Octadecatrienoic acid; AI3-23986; cis-Delta(9,12,15)-octadecatrienoic acid; (Z,Z,Z)-Octadeca-9,12,15-trienoic acid; CHEBI:27432; 0RBV727H71; MFCD00065720; LINOLENIC ACID (18:3 n-3); 9,12,15-all-cis-Octadecatrienoic acid; NCGC00091058-04; Linolenic acid, 99%; DSSTox_CID_5506; cis-9, cis-12, cis-15-octadecatrienoic acid; DSSTox_RID_77815; (9Z,12Z,15Z)octadeca-9,12,15-trienoic acid; DSSTox_GSID_25506; alpha-LA; CAS-463-40-1; SMR000857336; C18:3n-3,6,9; (9Z,12Z,15Z)-Octadecatrienoate; Linolenic acid, crude; cis,cis,cis-9,12,15-octadecatrienoate; a-Linolenate; cis-9,12,15-octadecatrienoic acid; cis,cis-9,12,15-Octadecatrienoic acid; (9Z,12Z,15Z)-9,12,15-Octadecatrienoic acid; NSC 2042; alpha-linolenic-acid; EINECS 207-334-8; C18:3; Linolenic acid, >=99%; SCHEMBL15282; 9,12,15-Octadecatrienoate; BSPBio_001376; 68424-45-3; MLS001336029; MLS001336030; MLS002454413; BML3-B05; GTPL1049; Linolenic acid, ~70% (GC); DTXSID7025506; cid_5280934; cis-9,12,15-octadecatrienoate; NSC2042; FA005; HMS1361E18; HMS1791E18; HMS1989E18; HMS2233C13; HMS3402E18; HMS3649H05; Linolenic acid, analytical standard; CMC_7371; HY-N0728; NSC-2042; ZINC3802189; all-cis-9,15-Octadecatrienoic acid; Tox21_111071; Tox21_201727; Tox21_303322; all-cis-9,12,15-Octadecatrienoate; BDBM50240347; LMFA01030152; SBB069548; AKOS016008598; DB00132; (Z,Z,Z)-9,12,15-Octadecatrienoate; 9-cis,12-cis,15-cis-octadecatrienoate; IDI1_033846; Linolenic acid 10 microg/mL in Methanol; NCGC00091058-01; NCGC00091058-02; NCGC00091058-05; NCGC00091058-06; NCGC00091058-07; NCGC00091058-08; NCGC00091058-09; NCGC00091058-10; NCGC00257192-01; NCGC00259276-01; (all-Z)-9,12,15-Octadecatrienoic acid; 9,15-Octadecatrienoic acid, (Z,Z,Z)-; AS-57338; M621; ST072192; 9(Z),12(Z),15(Z)-Octadecatrienoic acid; cis-9,cis-12,cis-15-Octadecatrienoic acid; CS-0009741; L0050; cis,cis,cis-octadeca-9,12,15-trienoic acid; Octadecatrienoic acid, 9,12,15-(Z,Z,Z)-; A-8311; C06427; Linolenic acid, Vetec(TM) reagent grade, 98%; L000707; Q256502; SR-01000838327; SR-01000838327-2; 2DCD0473-E5CC-47BB-A0A4-95899AFF6C4B; BRD-K33396764-001-02-0; 9,12,15-Octadecatrienoic acid, (9Z,12Z,15Z)- (9CI); UNII-0JXR8F0V1Q component DTOSIQBPPRVQHS-PDBXOOCHSA-N; UNII-5U9XZ261ER component DTOSIQBPPRVQHS-PDBXOOCHSA-N; UNII-71M78END5S component DTOSIQBPPRVQHS-PDBXOOCHSA-N; UNII-96GS7P39SN component DTOSIQBPPRVQHS-PDBXOOCHSA-N; UNII-F85N2YHE4E component DTOSIQBPPRVQHS-PDBXOOCHSA-N; UNII-HBA528N3PW component DTOSIQBPPRVQHS-PDBXOOCHSA-N; alpha-Linolenic acid, 1.0 mg/mL in ethanol, certified reference material
Click to Show/Hide
|
||||
| Species Origin | Perilla frutescens ... | Click to Show/Hide | |||
| Perilla frutescens | |||||
| Disease | Ulcerative colitis [ICD-11: DD71] | Investigative | [1] | ||
| Structure |
|
Click to Download Mol2D MOL |
|||
| ADMET Property |
Absporption
Caco-2 Permeability
-5.054
MDCK Permeability
-4.81
PAMPA
- - -
HIA
- - -
Distribution
VDss
-0.465
PPB
98.2%
BBB
- - -
Metabolism
CYP1A2 inhibitor
- - -
CYP1A2 substrate
- - -
CYP2C19 inhibitor
- - -
CYP2C19 substrate
- - -
CYP2C9 inhibitor
- - -
CYP2C9 substrate
+++
CYP2D6 inhibitor
- - -
CYP2D6 substrate
+++
CYP3A4 inhibitor
- - -
CYP3A4 substrate
- - -
CYP2B6 inhibitor
+++
CYP2B6 substrate
+++
CYP2C8 inhibitor
+++
HLM Stability
- - -
Excretion
CLplasma
4.648
T1/2
0.354
Toxicity
DILI
- - -
Rat Oral Acute Toxicity
- - -
FDAMDD
- - -
Respiratory
+++
Human Hepatotoxicity
- - -
Ototoxicity
- - -
Drug-induced Nephrotoxicity
-
Drug-induced Neurotoxicity
- - -
Hematotoxicity
- - -
Genotoxicity
- - -
Tips: 1. For the classification endpoints, the prediction probability values are transformed into six symbols: 0-0.1 (- - -), 0.1-0.3 (- -), 0.3-0.5 (-), 0.5-0.7 (+), 0.7-0.9 (++), and 0.9-1.0 (+++).
2. Additionally, the corresponding relationships of the three labels are as follows: excellent; medium; poor.
Click to Show/Hide
|
||||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
| Formula |
C18H30O2
|
||||
| PubChem CID | |||||
| Canonical SMILES |
CCC=CCC=CCC=CCCCCCCCC(=O)O
|
||||
| InChI |
1S/C18H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h3-4,6-7,9-10H,2,5,8,11-17H2,1H3,(H,19,20)/b4-3-,7-6-,10-9-
|
||||
| InChIKey |
DTOSIQBPPRVQHS-PDBXOOCHSA-N
|
||||
| CAS Number |
CAS 463-40-1
|
||||
| ChEBI ID | |||||
| Herb ID | |||||
| SymMap ID | |||||
| TCMSP ID | |||||
| TTD Drug ID | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
| Riluzole | Motor neuron disease | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | KCNK2 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | KCNK4 | Molecule Info | |||
| In-vivo Model | Focal ischemia was induced in adult male C57/Bl6 mice by occlusion of the left middle cerebral artery (MCA) using an intraluminal filament technique. | |||||
| Experimental
Result(s) |
Alpha-linolenic acid and riluzole treatment confer cerebral protection and improve survival after focal brain ischemia. | |||||
| β. A List of Drug(s) Whose Adverse Effect can be Decreased by This NP | ||||||
| Gentamicin | Bacterial infection | Click to Show/Hide the Molecular Data of This Drug | ||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [3] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | COX-2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | NOS2 | Molecule Info |
Pathway MAP
|
||
| In-vivo Model | Eight-week-old balb/c albino male mice were used in this study. | |||||
| Experimental
Result(s) |
The gentamicin administration causes nephrotoxicity and the use of alpha-linolenic acid can be helpful against this toxic effect. | |||||
| Cisplatin | Bladder cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [4] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | COX-2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | NOS2 | Molecule Info |
Pathway MAP
|
||
| In-vivo Model | Male BALB/c albino mice weighing 30 g were used in this study. | |||||
| Experimental
Result(s) |
ALA, an n-3 fatty acid, has a protective effect in mice renal tissue. | |||||
| Doxorubicin | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [5] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
| In-vivo Model | Male Sprague-Dawley rats weighing 220+ 20 were used in this study. | |||||
| Experimental
Result(s) |
Alpha-Linolenic acid attenuates doxorubicin-induced cardiotoxicity in rats through suppression of oxidative stress and apoptosis. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Gprotein coupled receptor 120 (GPR120) | Molecule Info | [6] | |
| Gprotein coupled receptor 40 (GPR40) | Molecule Info | [7] | ||
| Prostaglandin G/H synthase 2 (COX-2) | Molecule Info | [8] | ||
| BioCyc | Aspirin-triggered lipoxin biosynthesis | Click to Show/Hide | ||
| 2 | Aspirin triggered resolvin D biosynthesis | |||
| 3 | C20 prostanoid biosynthesis | |||
| 4 | Aspirin triggered resolvin E biosynthesis | |||
| KEGG Pathway | Insulin secretion | Click to Show/Hide | ||
| 2 | Arachidonic acid metabolism | |||
| 3 | Metabolic pathways | |||
| 4 | NF-kappa B signaling pathway | |||
| 5 | VEGF signaling pathway | |||
| 6 | TNF signaling pathway | |||
| 7 | Retrograde endocannabinoid signaling | |||
| 8 | Serotonergic synapse | |||
| 9 | Ovarian steroidogenesis | |||
| 10 | Oxytocin signaling pathway | |||
| 11 | Regulation of lipolysis in adipocytes | |||
| 12 | Leishmaniasis | |||
| 13 | Pathways in cancer | |||
| 14 | Chemical carcinogenesis | |||
| 15 | MicroRNAs in cancer | |||
| 16 | Small cell lung cancer | |||
| NetPath Pathway | IL1 Signaling Pathway | Click to Show/Hide | ||
| 2 | TSH Signaling Pathway | |||
| 3 | IL4 Signaling Pathway | |||
| 4 | TGF_beta_Receptor Signaling Pathway | |||
| 5 | IL5 Signaling Pathway | |||
| Panther Pathway | Endothelin signaling pathway | Click to Show/Hide | ||
| 2 | Inflammation mediated by chemokine and cytokine signaling pathway | |||
| 3 | Toll receptor signaling pathway | |||
| 4 | CCKR signaling map ST | |||
| Pathwhiz Pathway | Arachidonic Acid Metabolism | Click to Show/Hide | ||
| Pathway Interaction Database | Calcineurin-regulated NFAT-dependent transcription in lymphocytes | Click to Show/Hide | ||
| 2 | S1P1 pathway | |||
| 3 | C-MYB transcription factor network | |||
| 4 | Signaling mediated by p38-alpha and p38-beta | |||
| 5 | Calcium signaling in the CD4+ TCR pathway | |||
| Reactome | G alpha (q) signalling events | Click to Show/Hide | ||
| 2 | Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion | |||
| WikiPathways | GPCRs, Class A Rhodopsin-like | Click to Show/Hide | ||
| 2 | Incretin Synthesis, Secretion, and Inactivation | |||
| 3 | Gastrin-CREB signalling pathway via PKC and MAPK | |||
| 4 | Integration of energy metabolism | |||
| 5 | GPCR ligand binding | |||
| 6 | GPCR downstream signaling | |||
| 7 | Prostaglandin Synthesis and Regulation | |||
| 8 | Arachidonic acid metabolism | |||
| 9 | Aryl Hydrocarbon Receptor | |||
| 10 | Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis | |||
| 11 | Spinal Cord Injury | |||
| 12 | Integrated Pancreatic Cancer Pathway | |||
| 13 | Eicosanoid Synthesis | |||
| 14 | Selenium Micronutrient Network | |||